Effects of Curcumin-Piperine Supplementation in Fibromyalgia

NCT07753018 · tracked via the Priya Life Science Egypt tracker

Sponsor

Ain Shams University

Phase

Phase 2

Started

2026-08-01

Last updated

2026-08-11

Condition(s) studied

Fibromyalgia (FM)

Investigational drug(s) / intervention(s)

Curcumin - PiperinePlacebo

Curcumin - Piperine: The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract).

Placebo: the placebo group will receive matching oral placebo tablet containing inert excipients for the same duration. The placebo tablets will be identical in appearance, size, color, and packaging to the active supplement to maintain blinding.

Study summary

The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.

Participants will:

Be randomly assigned to receive either curcumin and piperine supplements or a placebo.

Attend scheduled clinic visits for clinical assessments and blood sample collection.

Complete study questionnaires before and after treatment time frame.

The primary question the study aim to answer is:

Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?

The secondary questions this study aims to answer are:

Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Adult women aged ≥18 years. * Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria. Exclusion Criteria: * Diabetic patients (HbA1c ≥ 6.5). * Patients with chronic inflammatory or autoimmune diseases other than FM. * Patients allergic to curcumin or piperine. * Patients receiving other anti-inflammatory medications. * Severe hepatic or renal impairment. * Patients receiving anticoagulant medications (e.g., clopidogrel). * Pregnancy or lactation. * Participation in another clinical trial

Primary outcome measure(s)

Assessment of pain severity measured by the Visual Analog Scale (VAS) — 3 months
VAS is a self-administered instrument widely used in fibromyalgia research and clinical practice to assess pain intensity and monitor treatment response. The VAS uses a 10-cm horizontal line anchored by 0 (no pain) and 10 (worst imaginable pain). It will be measured at baseline, after 1 month, and after 3 months.

Trial sites (1)

Facility	City	Region	Status
Suez Canal University hospitals	Ismailia	Egypt

More Ain Shams University trials in Egypt

Longitudinal Oral Health Changes After Head and Neck Radiotherapy Active, not recruiting

Efficacy of Statins Among Major Depressive Disorder Recruiting

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients Recruiting

The Rapid Shallow Breathing Index (RSBI) is a Widely Used Predictor for Weaning Patients From Mechanical Ventilation This Study Aims to Determine the Predictive Value of RSBI Measurements for Extubation Success in Mechanically Ventilated ICU Patients Recruiting

Use of TEE Derived Measurement vs Direct Measurement Under General Anesthesia in Assessment of Pressure Gradient in Peri Membranous Ventricular Septal Defect Starting soon

Other trials for the same condition

Silymarin vs Hesperidin/Diosmin in Fibromyalgia Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07753018 on ClinicalTrials.gov ↗ ← All trials in Egypt